Method Profile
Establish prostate cancer organoids from additional targeted biopsy cores and compare three drug responses.
Feasibility and exploratory pharmacology when surgical tumor material is unavailable.
12 prostate adenocarcinoma biopsy samples yielded organoids. Nine with adequate proliferation entered downstream characterization and drug screening.
Two additional MRI/ultrasound fusion-targeted cores supplied research material. The 384-well assay used 48-hour culture followed by 96-hour drug exposure.
Drugs
Enzalutamide and docetaxel 0.0032–10 μM; olaparib 0.0039–4 μM.
Validation readouts
H&E, cytokeratin/androgen-receptor staining, whole-exome mutation/copy-number comparison and CellTiter-Glo 3D.
Compare each culture with its parental biopsy and fit drug-response curves separately for each model.
Targeted-biopsy feasibility and between-model pharmacology.
13 participants sampled; one without detected tumor excluded. Twelve cultures were established and nine proliferated adequately for screening.
Parental biopsy; matched normal blood in genomic analysis; drug controls and other organoid models.
Models retained histological and androgen-receptor features and many genomic alterations. Individual models showed different enzalutamide, docetaxel and olaparib responses.
An exploratory study established organoids from all 12 cancer-positive targeted biopsy samples, with nine growing sufficiently for downstream assays. Responses to enzalutamide, docetaxel and olaparib varied among the models.
